Axol is a leading provider of iPSC product and service solutions for neuroscience and cardiac modelling in drug discovery and screening applications. Our custom research capabilities in gene editing, electrophysiology, reprogramming, and differentiation means we can offer customers validated ready-to-use cell lines and a suite of services bolstered by deep scientific expertise and robust functional data - all with shorter lead times.
With the widespread and rapid uptake of iPSC-based products and technologies for use in drug development R&D and screening, there is a growing call from users for better reproducibility and consistency in these increasingly critical tools.
To meet that moment, Axol is committed to being an industry leader in applying robust quality systems to the development and manufacture of iPSC products. We recently took a critical first step of obtaining ISO:9001 certification at our manufacturing site in Edinburgh, Scotland.
We have implemented a quality policy that articulates our three guiding principles:
Commitment to a quality culture
Commitment to a customer focus
Commitment to regulatory compliance
These are only the first steps in a quality journey to ensure that everything we produce is consistently made, data is accurately documented, and changes to product are communicated to the customers who trust us to deliver the models and discovery tools that they rely on.
Wednesday, 18th November, 2020
10:00am GMT (UTC+0)
hosted by Lilly Xu, Ph.D. Senior Vice President, DMPK & Exploratory Toxicology Dept, ChemPartner